Insider Trading Alert - OMCL, NPTN And XNCR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 14, 2015, 102 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $67.14 to $168,133,945.20.

Highlighted Stocks Traded by Insiders:

Omnicell (OMCL) - FREE Research Report

Petersmeyer Gary S, who is Director at Omnicell, sold 670 shares at $34.74 on May 14, 2015. Following this transaction, the Director owned 15,685 shares meaning that the stake was reduced by 4.1% with the 670-share transaction.

The shares most recently traded at $35.95, up $1.21, or 3.37% since the insider transaction. Historical insider transactions for Omnicell go as follows:

  • 4-Week # shares sold: 2,515
  • 12-Week # shares sold: 3,855
  • 24-Week # shares sold: 14,918

The average volume for Omnicell has been 185,600 shares per day over the past 30 days. Omnicell has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 4.65% year-to-date as of the close of trading on Thursday.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates in two segments, Automation and Analytics, and Medication Adherence. The company has a P/E ratio of 42.5. Currently, there are 3 analysts who rate Omnicell a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMCL - FREE

TheStreet Quant Ratings rates Omnicell as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Omnicell Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NeoPhotonics (NPTN) - FREE Research Report

Cheung Chiyue, who is Chief Operating Officer at NeoPhotonics, sold 13,420 shares at $6.89 on May 14, 2015. Following this transaction, the Chief Operating Officer owned 0 shares meaning that the stake was reduced by 100% with the 13,420-share transaction.

The shares most recently traded at $7.12, up $0.23, or 3.23% since the insider transaction. Historical insider transactions for NeoPhotonics go as follows:

  • 4-Week # shares bought: 68,500
  • 12-Week # shares bought: 68,500
  • 12-Week # shares sold: 6,200
  • 24-Week # shares bought: 68,500
  • 24-Week # shares sold: 6,200

The average volume for NeoPhotonics has been 365,600 shares per day over the past 30 days. NeoPhotonics has a market cap of $216.8 million and is part of the technology sector and electronics industry. Shares are up 94.97% year-to-date as of the close of trading on Thursday.

NeoPhotonics Corporation designs and manufactures hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks. Currently, there are 3 analysts who rate NeoPhotonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NPTN - FREE

TheStreet Quant Ratings rates NeoPhotonics as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full NeoPhotonics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Xencor (XNCR) - FREE Research Report

Baracchini Edgardo Jr, who is Chief Business Officer at Xencor, sold 200 shares at $15.00 on May 14, 2015. Following this transaction, the Chief Business Officer owned 1,604 shares meaning that the stake was reduced by 11.09% with the 200-share transaction.

The shares most recently traded at $15.03, up $0.03, or 0.2% since the insider transaction. Historical insider transactions for Xencor go as follows:

  • 4-Week # shares sold: 400
  • 12-Week # shares sold: 400
  • 24-Week # shares sold: 400

The average volume for Xencor has been 242,100 shares per day over the past 30 days. Xencor has a market cap of $590.1 million and is part of the health care sector and drugs industry. Shares are down 8.85% year-to-date as of the close of trading on Thursday.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Currently, there are 3 analysts who rate Xencor a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XNCR - FREE

TheStreet Quant Ratings rates Xencor as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Xencor Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists